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Abstract: Objective: Enhanced external counterpulsation (EECP) and ranolazine are approved treatments for patients with chronic stable angina by the United States Food and Drug Administration (FDA). Whether EECP offers
clinical benefits regardless of underlying ranolazine therapy needs further investigation. Methods: This was a retrospective evaluation of patients referred to a specialized EECP center. Patients having data on 6-Minute Walk
Distance (6MWD) or Duke Activity Status Index (DASI) were categorized into two groups (EECP with ranolazine or
EECP only). The primary endpoints were change in 6MWD and DASI before and after a full course of EECP within
each of the two groups. Inter-group differences were also assessed. The Wilcoxon test was utilized to compare
the change from baseline within each group and the Mann-Whitney U test to compare difference between groups.
Results: A total of 2836 patient records (age 66.9 ± 10 years) were identified (1193 in EECP and ranolazine group
and 1643 in EECP only group). EECP added to baseline ranolazine resulted in a statistically significant improvement
in 6MWD and DASI (+126 feet (IQR: 230 feet), and +13.35 (IQR: 17.11), respectively, P<0.001 for both). Similarly,
the EECP only group showed a statistically significant improvement in 6MWD and DASI (+140 feet (IQR: 225 feet)
and +13.49 (IQR: 18.02), respectively, P<0.001 for both). There was no statistically significant difference between
the two groups when comparing the change from baseline in 6MWD and DASI score (P=0.256 and P=0.056 respectively). Conclusion: EECP improves markers of functional capacity regardless of baseline ranolazine therapy. EECP’s
unique safety profile advocates for its early consideration in the treatment algorithm.
Keywords: EECP, ranolazine, chronic stable angina, functional capacity, quality of life

Introduction
In the United States, 9.4 million people over
the age of 20 suffer from angina [1]. Class I
recommendations for the management of chronic stable angina (CSA) include pharmacologic interventions such as beta-adrenergic
blockers, calcium channel blockers, and nitrates along with invasive modalities including
percutaneous coronary interventions (PCI) and
coronary artery bypass grafts (CABG) [2]. Despite optimized pharmacotherapy and surgical
interventions, refractory angina affects an estimated 600000 to 1.8 million people within
the United States with an approximate 50000
to 100000 newly diagnosed cases each year
[3]. This population has a high incidence of
hospitalization secondary to their burden of
disease with an estimated average cost of
$10080 per hospitalization [4].

Ranolazine is approved by the United States
Food and Drug Administration (FDA) as add-on
therapy to Class I agents for the treatment of
CSA (Class IIa, level B) [2, 5]. Enhanced external counterpulsation (EECP) is an FDA approved non-invasive device for treatment of patients with chronic stable angina or heart failure (Class IIb, level B) [2]. A full course of EECP
therapy typically consists of 1-hour sessions 5
days per week for 7 weeks, totaling 35 sessions [2, 6].
EECP treatment is relatively well tolerated with
side effects primarily related to device use [7].
Multiple studies have found that EECP improves markers of functional capacity such as
6-Minute Walk Distance (6MWD) and Duke
Activity Status Index (DASI) [8, 9]. While these
results are promising, they are limited by small
study populations (under 200 patients) and
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have yet to explore the isolated degree of benefit from EECP when added to baseline ranolazine therapy [10]. EECP therapy is one of only
two guideline supported non-pharmacologic
treatment modalities that mechanistically improves myocardial perfusion to relieve symptoms of refractory angina [11]. With the generic
availability of ranolazine as of February 2019
and emerging data supporting the clinical use
of non-pharmacologic treatments like EECP,
understanding the magnitude of benefit EECP
has when added to ranolazine therapy is particularly warranted [11, 12]. The intent of our
study was to investigate whether EECP offers
clinical benefits independent of underlying
ranolazine therapy.
Methods
Study design
This retrospective analysis was approved by
the Institutional Review Board at the University
of the Pacific. All patients receiving care at
Flow Therapy clinics with a diagnosis of angina
from April 2013 to October 2018 with data on
6MWD and DASI were eligible for inclusion in
the analysis (n=2836 records).
Patients were allocated into either the EECP
and ranolazine (EECP+R) or EECP only groups
according to baseline ranolazine usage. Patients were included if they had pre- and postdata on 6MWD or DASI. Data was extracted
from the outpatient clinic’s electronic health
record with a Python script (Python version
3.7) written to extract the following data: patient identification, age, gender, comorbidities,
baseline medications, pre- and post-6MWD
(feet), pre- and post-DASI, and baseline CCS
angina class.
The pre-specified primary endpoints were changes from baseline in 6MWD and DASI after a
full course of EECP treatment in patients with
and without ranolazine therapy. The 6MWD is
validated measurement of exercise functional
capacity commonly used to assess responses
to medical interventions in patients suffering
from chronic cardiovascular and pulmonary diseases [13, 14]. The 6MWD is a strong predictor
of cardiovascular events in patients with stable
coronary heart disease and an independent
measure of morbidity and mortality amongst
patients suffering from congestive heart failure
and chronic obstructive pulmonary disease
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[11, 15]. The test measures the distance patients are able to walk on a flat, hard surface in
a duration of 6 minutes and is a predictor of
health outcomes in stable coronary heart disease, heart failure, pulmonary hypertension,
and pulmonary disease [13, 14]. The DASI is a
validated 12 item questionnaire used to measure health-related quality of life specific to
cardiovascular functional status [12-14]. The
questionnaire provides independent prognostic information for long-term adverse clinical
events in stable cardiac patients, as well as an
indicator of mortality in patients with chronic
heart failure [15-17]. Due to the retrospective
nature of this analysis, all patients treated with
a full course of EECP and not on baseline ranolazine therapy were considered as a comparator group.
Patients who visited the center for multiple
treatment courses were included in the overall
analysis. Patients not completing at least 30
EECP sessions were excluded from analyses. A
sensitivity analysis was performed to assess
changes in the primary endpoints in patients
having gone through only 1 full course (1
round) of EECP, having a baseline Canadian
Cardiovascular Society (CCS) angina class ≥3
or with heart failure.
Statistical analysis
We performed the Wilcoxon test to compare
the change from baseline within each group
(intra-group) and the Mann Whitney U-test was
utilized to compare the changes from baseline
in the EECP+R and EECP only groups (intergroup). A P<0.05 was considered statistically
significant. A Fisher’s exact was performed to
assess differences in categorical variables. All
data are represented as median and interquartile range. All analysis was done using Python
script (Python version 3.7).
Results
Baseline demographics
A total of 2836 patient records were identified having available data for 6MWD or DASI
(1193 (42.1%) in the EECP+R group and 1643
(58.0%) patients in the EECP only group). Of
those enrolled 2312 unique patients completed only one course of EECP. Overall, patients
were predominantly male (70.0%) with an aver-
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Table 1. Baseline demographics
Demographic
Average Age
Male
CABG
PCI
CAD
Diabetes
Heart Failure
Hyperlipidemia
Hypertension
Myocardial Infarction
6MWD
DASI
ACE Inhibitors
ARB
Alpha blockers
Aspirin
Blood Thinner†
Beta blockers
Calcium Channel Blockers
Digoxin
Diuretics
Nitrates
Omega Fatty Acids
Statins

EECP+R
(n=1193)
66.0 ± 11
838 (70%)
715 (60%)
396 (33%)
1174 (98%)
591 (50%)
385 (32%)
997 (84%)
1091 (92%)
591 (50%)
1175 ± 381
9.7 ± 10
412 (35%)
310 (30%)
39 (3%)
988 (83%)
790 (66%)
956 (80%)
342 (29%)
28 (2%)
439 (37%)
994 (83%)
213 (18%)
988 (83%)

EECP Only
(n=1643)
67.6 ± 10
1144 (70%)
818 (50%)
522 (32%)
1612 (98%)
722 (44%)
654 (40%)
1363 (83%)
1459 (89%)
760 (46%)
1105 ± 390
10.3 ± 15
540 (33%)
402 (25%)
44 (3%)
1236 (75%)
945 (56%)
1246 (76%)
421 (26%)
56 (3%)
683 (42%)
974 (59%)
232 (14%)
1280 (78%)

ACE inhibitor, Angiotensin-Converting Enzyme Inhibitor; ARB,
Angiotensin II receptor blockers; 6MWD, 6-Minute Walk
Distance; CABG, Coronary Artery Bypass Grafts; CAD, Coronary Artery Disease; CCS, Canadian Cardiovascular Society;
DASI, Duke Activity Status Index; EECP, Enhanced External
Counterpulsation; EECP+R, EECP and Ranolazine Group; PCI,
Percutaneous Coronary Interventions. †including antiplatelet
agents (ticagrelor and prasugrel) and direct oral anticoagulants (apixaban and rivaroxaban).

age age of 66.9 ± 10. Of the patients included 98.2% had coronary artery disease (CAD),
36.6% had heart failure, 46.3% had diabetes,
83.2% had concomitant hyperlipidemia, and
89.9% had hypertension. Nearly 42.0% (n=
1193) of the overall cohort were on ranolazine
therapy at baseline (Table 1).
Outcomes in EECP+R Group
Post EECP therapy, all patients on baseline
ranolazine (EECP+R group) showed a statistically significant improvement in 6MWD (+126
ft (IQR 230), P<0.001) and DASI (+13.35 (IQR
17.11), P<0.001). When limiting the model to
patients completing 1 round only, statistical595

ly significant improvements were shown in
6MWD (+125 ft (IQR 230), P<0.001) and DASI
(+13.5 (IQR 18.45), P<0.001). Further, patients
with a CCS angina class ≥3 also demonstrated significant improvements in 6MWD (+130
ft (IQR 230), P<0.001) and DASI (+13.44 (IQR
17.04), P<0.001). Likewise, when limited to
patients with heart failure, results maintained
significance for each of the study end points
(6MWD +135 ft (IQR 249), P<0.001 and DASI
+11.49 (IQR 16.25), P<0.001). Figures 1 and 2
describe the change in 6MWD and DASI for the
EECP+R and EECP only groups.
Outcomes in EECP only group
The EECP only cohort similarly showed a statistically significant improvement in 6MWD (+140
ft (IQR 225), P<0.001) and DASI (+13.49 (IQR
18.02), P<0.001). In participants completing 1
round only, improvements in 6MWD (+140 ft
(IQR 225), P<0.001) and DASI (+13.56 (IQR
18.45), P<0.001) were also statistically significant. Statistical significance was maintained
when limiting analysis to CCS angina class of
≥3 (6MWD +140 ft (IQR 225), P<0.001 and
DASI +13.49 (IQR 18.01), P<0.001). Similarly,
improvements in 6MWD (+135 ft (IQR 235),
P<0.001) and DASI (+11.69 (IQR 17.85), P<
0.001) were statistically significant when limited to patients with heart failure.
Outcomes comparing EECP+R vs. EECP only
groups
There were no statistically significant differences for 6MWD and DASI between the EECP+R and EECP only groups (P=0.2560 and
P=0.0558 respectively) (Table 2). This was
true across all subgroups for both endpoints
(all p-values >0.05).
Discussion
Our findings indicate EECP therapy improves
markers of functional capacity regardless of
baseline ranolazine therapy. These benefits
were maintained after limiting the analysis to
participants completing only 1 course of EECP,
having CCS angina class of ≥3, or having heart
failure.
The magnitude of change for 6MWD (>125
ft) is clinically meaningful. Generally, improvements ranging from 82 ft (25 m) to 229 ft (70
m) in 6MWD are associated with enhanced
Am J Cardiovasc Dis 2020;10(5):593-601
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with a 54% higher risk of death
(age-adjusted HR 1.54, 95% CI
1.32-1.80) and a 55% increased risk of any cardiovascular
event (age-adjusted HR 1.55,
95% CI 1.35-1.78) [14].

Figure 1. Improvement from baseline in 6MWD for EECP+R and EECP only.
Patients in the EECP+R group showed a statistically significant improvement in 6MWD of +126 ft (IQR 230) with P<0.001 from baseline. Likewise,
patients in the EECP only group showed a statistically significant improvement from baseline in 6MWD of +140 ft (IQR 225) with P<0.005. The intergroup analysis between the two groups was not statistically significant
(P>0.05). Abbreviations: 6MWD, 6-Minute Walk Distance; EECP, Enhanced
external counterpulsation; EECP+R, EECP and ranolazine.

The improvement in DASI in
both groups was approximately 13 points. A change of
4-6 points in DASI score is
associated with improved clinical outcomes [20-22]. A study evaluating the prognostic
value of the DASI on 1700 stable, non-acute coronary syndrome patients with heart failure found that DASI scores in
the lowest quartile were at a
3.3 fold increased risk in 5
year mortality as compared to
the highest score quartile (HR
3.33, 95% CI 2.57-4.36, P<
0.0001) [23].

Our results parallel previous
findings showing EECP’s independent improvement in markers of functional capacity. A
prospective, longitudinal pilot
study by Wu et al, assessed
changes from baseline in 6MWD 6 months post EECP therapy in 34 patients with refractory angina. They found 6MWD
improved from 1345 ft (410 m)
at baseline to 1440 ft (439 m)
(P<0.01) post treatment (+95
ft (29 m)). The change evident
in our EECP only group is higher than that observed by Wu et
al; this may be due to our
Figure 2. Improvement from baseline in DASI for EECP+R and EECP only.
patient population being at a
Patients in the EECP+R group had a statistically significant improvement
lower baseline functional cafrom baseline DASI score of +13.35 (IQR 17.11) with P<0.001. Patients in
the EECP only cohort also showed a statistically significant improvement
pacity, the low sample size in
in DASI of +13.49 (IQR 18.02) with a P<0.001. Intergroup analysis did not
the study by Wu et al, or better
show a statistically significant difference in improvement in DASI (P>0.05).
EECP care provided by the parAbbreviations: DASI, Duke Activity Status Index; EECP, Enhanced external
ticular centers in our analyses
counterpulsation; EECP+R, EECP and ranolazine.
[8]. EECP has also shown independent positive effects on
clinical outcomes and mortality benefits [13,
DASI scores. A prospective analysis of 13
18, 19]. A study conducted by Beatty et al
patients with chronic stable angina found that
found that in patients with stable coronary
after completion of a full course of EECP theraheart disease, each standard deviation reducpy there were marked improvements in DASI
tion in 6MWD (341 ft [104 m]) was associated
scores (12 ± 2 vs. 19 ± 3; P=0.03) [9].
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Table 2. Change in markers of functional capacity
Population
6MWD (feet)
All Patients
Round 1 Only
≥3CCS
HF Only
DASI
All Patients
Round 1 Only
≥3CCS
HF Only

N

Change in EECP+R, Median (IQR)

N

Change in EECP Only, Median (IQR)

P-value

1104
859
1033
350

126 (230)
125 (230)
130 (230)
135 (249)

1545
1305
1401
609

140 (225)
140 (225)
140 (225)
135 (235)

0.256
0.173
0.425
0.203

900
728
845
293

13.35 (17)
13.50 (18)
13.44 (17)
11.49 (16)

1279
1122
1164
499

13.49 (18)
13.56 (18)
13.49 (18)
11.69 (17)

0.056
0.130
0.061
0.330

CCS, Canadian Cardiovascular Society; DASI, Duke Activity Status Index; EECP, Enhanced external counterpulsation; EECP+R,
EECP and ranolazine; HF, heart failure; IQR, Interquartile Range; 6MWD, 6-Minute Walk Distance.

For comparison, ranolazine added to standard
of care therapy improves 6MWD and DASI by
37.7 ft (11.5 m) (992.5 ft (302.5 m) ± 423.2 ft
(129.0 m) baseline to 1030.2 ft (314.0 m) ±
418.3 ft (127.5 m) at 12 months) and 3.8 points (18.7 ± 14.9 baseline to 22.5 ± 15.8 at 12
months) respectively. These results were not
found to be statistically significant for either
endpoint [24, 25].
The magnitude of benefit seen in our results
can be explained by the fact that ranolazine
and EECP have differing mechanisms of action. EECP’s mechanism of action is similar to
an intra-aortic balloon pump where inflation
and deflation of the pneumatic cuffs during
diastole and systole are synchronized to heart
rhythm. This results in an increase in coronary
diastolic pressure and improved oxygen supply with retrograde aortic blood [26]. It is postulated that benefits observed with EECP therapy may be secondary to development of new
collateral blood vessels, improved endothelial
function and vascular reactivity, and enhanced
ventricular function [17, 27-29]. In contrast,
ranolazine is a piperazine derivative that inhibits late sodium channels in myocardial tissue.
While the exact mechanism of action of ranolazine is not fully realized, it has been known to
impede myocardial sodium overload leading to
improved myocardial relaxation, reduced ventricular rigidity, and subsequent improved myocardial perfusion [30]. Ranolazine does not
appear to effect heart rate or blood pressure
[31]. Our findings are not too surprising as based on a recent meta-analysis from the Cochrane Library, ranolazine add-on therapy only
improved angina frequency and did not pro597

vide any mortality or quality-of-life benefits
[32].
To our knowledge, this is the largest analysis
comparing the addition of EECP to ranolazine
and raises the question of EECP’s role in the
treatment of refractory angina. Elective surgical revascularization is a high cost and invasive procedure that while proven to improve
coronary ischemia, does not provide superior
results to medical optimization. In the Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation trial (COURAGE),
PCI added to optimized medical therapy did
not reduce the risk of death or myocardial
infarction in patients with objective myocardial
ischemia and coronary artery disease in comparison to patients receiving only optimized
medical therapy [33]. In the Bypass Angioplasty Revascularization Investigation 2 Diabetes
study (BARI 2D), CABG or PCI added to optimized medical therapy was found to be equivalent to optimized medical therapy in reducing
the risk of death or major adverse cardiovascular events (MACE) (death, MI, or stroke) [34].
The Percutaneous Coronary Intervention in
Stable Angina trial compared PCI to placebo in
medically optimized patients with angina. The
study found that PCI did not improve treadmill
exercise time as compared to placebo (16.6 s,
95% CI -8.9-42, P=0.20) [35].
More recently, in the landmark study International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
(ISCHEMIA) 5179 participants with stable ischemic heart disease and moderate or severe
ischemia on stress imaging or severe ischemia
based on non-imaging exercise tolerance testAm J Cardiovasc Dis 2020;10(5):593-601
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ing were randomized to receive optimal medical therapy or invasive surgical revascularization. The study results showed that initial invasive intervention, as compared to optimized
medical therapy, did not demonstrate a reduction in the study’s primary end point of time
to cardiovascular death, MI, hospitalization for
unstable angina, heart failure or resuscitated
cardiac arrest (Adjusted HR invasive vs. conservative 0.93 (0.80, 1.08); P=0.34) [33]. In
our analysis we found that even patients on
baseline ranolazine had clinical benefits from
the addition of EECP. Our results further support the early consideration of EECP for patients
with stable ischemic heart disease. As such,
it is plausible that EECP may provide enough
benefits to eliminate the addition of further
pharmacotherapeutic options in a population
with a pre-existing high pill burden.
Medication non-adherence in patients with cardiovascular disease varies from 24% to 60%,
and as a result one potential drawback to ranolazine use in patients with refractory angina is
that treatment requires long term medication
adherence [36-39]. Similarly, compliance with
the 35 sessions of EECP is not feasible for all
patients. However, after a full course of EECP
clinical benefits have been known to sustain
for up to 2 years. A long-term clinical outcomes
trial showed sustained reductions in CCS angina class in 55% of patients presenting at the
two year follow up [6]. While medication optimization remains the primary treatment for angina, using EECP earlier in the treatment algorithm can be a clinically astute strategy in
patients especially due to its safety profile and
having nearly no contraindications. This application warrants further exploration in future
studies.
Though our data suggests that EECP provides
clinically meaningful improvements independent of baseline ranolazine use, several limitations need to be considered. While this is the
largest analysis of this kind, interpretation is
limited by the retrospective study design and
lack of propensity score matching. We could
not control for background antianginal therapy
or medication dose optimization. Since this
data was extracted from an outpatient clinic,
without access to complete medical records,
advanced statistical techniques that control for
confounding variables could not be utilized. As
such, we accounted for baseline differences
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between the EECP+R and EECP only groups by
comparing the change from baseline rather
than the unadjusted absolute values for each
endpoint. Future studies would benefit from a
ranolazine only arm for comparison.
Conclusion
EECP improves clinically relevant endpoints of
6MWD and DASI by over 125 ft and 13 points
respectively. This observed benefit was independent of baseline ranolazine therapy. The
observed clinical benefit of EECP is likely driven by its different mechanism of action relative to ranolazine. EECP should be considered
earlier in management of angina and ischemic
heart disease independent of or complimentary to ranolazine therapy as a result of its superior safety profile, relatively high compliance
and sustained long-term benefits.
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